Key points are not available for this paper at this time.
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
Kantoff et al. (Thu,) studied this question.